Cinnamylidene ketones as potential modulators of multidrug resistance in mouse lymphoma and human colon cancer cell lines

In Vivo

Volumn 20, Issue 1, 2006, Pages 119-124

  Engi, Helga ^a   Gyémánt, Nóra ^a   Lóránd, Tamás ^b   Lévai, Albert ^c   Ocsovszki, Imre ^a   Molnár, Joseph ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Cinnamylidene ketones; Efflux pump; MDR reversal; Multidrug resistance; P glycoprotein

Indexed keywords

2 (2 METHOXYCINNAMYLIDENE) 3,4 DIHYDRO 2H NAPHTHALEN 1 ONE; 2 (2 METHOXYCINNAMYLIDENE)INDAN 1 ONE; 2 (2 NITROCINNAMYLIDENE) 3,4 DIHYDRO 2H NAPHTHALEN 1 ONE; 2 (2 NITROCINNAMYLIDENE)INDAN 1 ONE; 2 (BETA METHYLCINNAMYLIDENE)INDAN 1 ONE; 2 CINNAMYLIDENE 3,4 DIHYDRO 2H NAPHTHALEN 1 ONE; 2 CINNAMYLIDENECYCLOHEXANONE; 2 CINNAMYLIDENECYCLOPENTANONE; 2 CINNAMYLIDENEINDAN 1 ONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 3 CINNAMYLIDENE 1 THIOCHROMANONE; 3 CINNAMYLIDENE 1 THIOFLAVANONE; 3 CINNAMYLIDENECHROMANONE; 3 CINNAMYLIDENEFLAVANONE; 6 (2 METHOXYCINNAMYLIDENE) 6,7,8,9 TETRAHYDROCYCLOHEPTEN 5 ONE; 6 (2 NITROCINNAMYLIDENE) 6,7,8,9 TETRAHYDROCYCLOHEPTEN 5 ONE; 6 CINNAMYLIDENE 6,7,8,9 TETRAHYDROCYCLOHEPTEN 5 ONE; ANTINEOPLASTIC AGENT; CINNAMYLIDENE KETONE DERIVATIVE; CINNAMYLIDENEBENZOCYCLOALKANONE DERIVATIVE; CINNAMYLIDENECYCLOALKANONE DERIVATIVE; CYTOSTATIC AGENT; DOXORUBICIN; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG POTENTIATION; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; STRUCTURE ANALYSIS; T CELL LYMPHOMA;

EID: 30844455115     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Szabó D, Keyzer H, Kaiser HE and Molnár J: Reversal of multidrug resistance of tumor cells. Anticancer Res 20: 4261-4274, 2000.
2. Molnár J, Szabó D, Mándi Y, Mucsi I, Fischer J, Varga A, König S and Motohashi N: Multidrug resistance reversal in mouse lymphoma cells by heterocyclic compounds. Anticancer Res 18: 3033-3038, 1998.
3. Robert J: Multidrug resistance in oncology: diagnostic and therapeutic approaches. Eur J Clin Invest 29(6): 536-545, 1999.
4. Juliano RL and Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutant. Biochim Biophys Acta 455: 152-162, 1976.
5. Bradley G, Juranka PF and Ling V: Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87-128, 1988.
6. Murren JR: Modulating multidrug resistance: can we target this therapy? Clin Cancer Res 8: 633-635, 2002.
7. Dean M, Rzhetsky A and Allikmet R: The human ATP-binding casette (ABC) transporter superfamily. Genome Res 11: 1156-1166, 2001.
8. Limtrakul P, Anuchapreeda S and Buddhasukh D: Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 4(1): 13, 2004.
9. Fu L, Liang Y, Deng L, Ding Y, Chen L, Ye Y, Yang X and Pan Q: Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemother Pharmacol 53(4): 349-356, 2004.
10. Beck WT and Qian XD: Photoaffinity substrates for P-glycoprotein. Biochem Pharmacol 43: 89-93, 1992.
11. Safa AR: Photoaffinity labeling of P-glycoprotein in multidrug resistance cells. Cancer Inv 11(1): 46-56, 1993.
12. Ford JM and Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199, 1990.
13. Hohmann J, Molnár J, Redei D, Evanics F, Forgo P, Kálmán A, Argay Gy and Szabó P: Discovery and biological evaulation of a new family of potent modulators of multidrug resistance: reversal of multidmg resistance of mouse lymphoma cells by new natural jatrophane diterpenoids isolated from Euphorbia species. J Med Chem 45: 2415-2431, 2002.
14. Dimmock JR, Sidhu KK, Chen M, Li J, Quail JW, Allen TM and Kao GY: Synthesis and cytotoxic evaluation of some cyclic arylidene ketones and related oximes, oxime esters, and analogs. Can J Pharmaceut Sci 83: 852-858, 1994.
15. Dimmock, JR, Baker GB and Sutherland RG: Evaluation of 1-phenyl-1,3-undecadien-5-one and related compounds for antineoplastic and cytotoxic activity. Can J Pharmaceut Sci 10: 53-59, 1975.
16. Gyul'akhmedov LM and Akhmedova RSh: Condensation of cyclopentanone and cyclohexanone with some aromatic aldehydes. Azerbaidzhanskii Khimicheskii Zhurnal 6: 83-85, 1978.
17. Cornwell MM, Pastan I and Gottesmann M: Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262: 2166-2170, 1987.
18. Gruber A, Peterson C and Reizenstein P: D-verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro. Int J Cancer 41: 224-226, 1988.
19. Di Pietro A, Dayan G, Conseil E, Steinfels E, Krell T, Trompier D, Baubichon-Cortay H and Jault JM: P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domain to establish structure-function relationships. Brz J Med Biolog Res 32: 925-939, 1999.
20. Saponara S, Kawase M, Shah A, Motohashi N, Molnar J, Ugocsai K, Sparagli G and Fusi F: 3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7) as a new multidrug resistance reverting agent devoid of effects on vascular smooth muscle contractility. Br J Pharmacol 141(3): 415-422, 2004.
21. Molnar J, Gyemant N, Mucsi I, Molnar A, Szabo M, Kortvelyesi T, Varga A, Molnar P and Toth G: Modulation of multidrug resistance and apoptosis of cancer cells by selected caroteniods. In Vivo 18(2): 237-244, 2004.